Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Functional Roles of the E3 Ubiquitin Ligase UBR5 in Cancer.

Shearer RF, Iconomou M, Watts CK, Saunders DN.

Mol Cancer Res. 2015 Dec;13(12):1523-32. doi: 10.1158/1541-7786.MCR-15-0383. Epub 2015 Oct 13. Review.

2.

Professor Robert Sutherland FAA, AO (1947-2012).

Watts CK, Daly RJ.

Horm Mol Biol Clin Investig. 2013 Dec;16(3):113-4. doi: 10.1515/hmbci-2013-0046. No abstract available.

PMID:
25436862
3.

Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3).

Brooke DG, van Dam EM, Watts CK, Khoury A, Dziadek MA, Brooks H, Graham LJ, Flanagan JU, Denny WA.

Bioorg Med Chem. 2014 Feb 1;22(3):1029-39. doi: 10.1016/j.bmc.2013.12.041. Epub 2013 Dec 30.

PMID:
24398380
4.

Effects of EDD on p53 function are context-specific.

Watts CK, Saunders DN.

J Biol Chem. 2011 Jul 15;286(28):le13; author reply le14. doi: 10.1074/jbc.L110.182527. No abstract available.

5.

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.

O'Brien PM, Davies MJ, Scurry JP, Smith AN, Barton CA, Henderson MJ, Saunders DN, Gloss BS, Patterson KI, Clancy JL, Heinzelmann-Schwarz VA, Murali R, Scolyer RA, Zeng Y, Williams ED, Scurr L, Defazio A, Quinn DI, Watts CK, Hacker NF, Henshall SM, Sutherland RL.

Br J Cancer. 2008 Mar 25;98(6):1085-93. doi: 10.1038/sj.bjc.6604281. Epub 2008 Mar 18. Erratum in: Br J Cancer. 2008 Jun 3;98(11):1880. Murali, Rajmohan [added].

6.

Putative tumor suppressor EDD interacts with and up-regulates APC.

Ohshima R, Ohta T, Wu W, Koike A, Iwatani T, Henderson M, Watts CK, Otsubo T.

Genes Cells. 2007 Dec;12(12):1339-45.

7.

The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints.

Munoz MA, Saunders DN, Henderson MJ, Clancy JL, Russell AJ, Lehrbach G, Musgrove EA, Watts CK, Sutherland RL.

Cell Cycle. 2007 Dec 15;6(24):3070-7. Epub 2007 Sep 7.

PMID:
18073532
8.

EDD mediates DNA damage-induced activation of CHK2.

Henderson MJ, Munoz MA, Saunders DN, Clancy JL, Russell AJ, Williams B, Pappin D, Khanna KK, Jackson SP, Sutherland RL, Watts CK.

J Biol Chem. 2006 Dec 29;281(52):39990-40000. Epub 2006 Oct 30.

9.

A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells.

Butt AJ, Roberts CG, Seawright AA, Oelrichs PB, Macleod JK, Liaw TY, Kavallaris M, Somers-Edgar TJ, Lehrbach GM, Watts CK, Sutherland RL.

Mol Cancer Ther. 2006 Sep;5(9):2300-9.

10.

Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1.

Nahum A, Zeller L, Danilenko M, Prall OW, Watts CK, Sutherland RL, Levy J, Sharoni Y.

Eur J Nutr. 2006 Aug;45(5):275-82. Epub 2006 Mar 24.

PMID:
16565789
11.

Edd, the murine hyperplastic disc gene, is essential for yolk sac vascularization and chorioallantoic fusion.

Saunders DN, Hird SL, Withington SL, Dunwoodie SL, Henderson MJ, Biben C, Sutherland RL, Ormandy CJ, Watts CK.

Mol Cell Biol. 2004 Aug;24(16):7225-34.

12.

EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer.

Clancy JL, Henderson MJ, Russell AJ, Anderson DW, Bova RJ, Campbell IG, Choong DY, Macdonald GA, Mann GJ, Nolan T, Brady G, Olopade OI, Woollatt E, Davies MJ, Segara D, Hacker NF, Henshall SM, Sutherland RL, Watts CK.

Oncogene. 2003 Aug 7;22(32):5070-81.

PMID:
12902990
13.

Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs.

Eblen ST, Kumar NV, Shah K, Henderson MJ, Watts CK, Shokat KM, Weber MJ.

J Biol Chem. 2003 Apr 25;278(17):14926-35. Epub 2003 Feb 19.

14.

Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2.

Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, Leong GM, Ross RJ, Ho KK.

Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1016-21. Epub 2003 Jan 27.

15.

EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response.

Henderson MJ, Russell AJ, Hird S, Muñoz M, Clancy JL, Lehrbach GM, Calanni ST, Jans DA, Sutherland RL, Watts CK.

J Biol Chem. 2002 Jul 19;277(29):26468-78. Epub 2002 May 13.

17.

Estrogen and progestin regulation of cell cycle progression.

Sutherland RL, Prall OW, Watts CK, Musgrove EA.

J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):63-72. Review.

PMID:
10819505
18.

Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs.

Callaghan MJ, Russell AJ, Woollatt E, Sutherland GR, Sutherland RL, Watts CK.

Oncogene. 1998 Dec 31;17(26):3479-91.

19.

c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.

Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL.

Mol Cell Biol. 1998 Aug;18(8):4499-508.

20.

Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells.

deFazio A, Chiew YE, McEvoy M, Watts CK, Sutherland RL.

Cell Growth Differ. 1997 Aug;8(8):903-11.

22.

The third human isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) map position 10p14-p15.

Nicholl J, Hamilton JA, Sutherland GR, Sutherland RL, Watts CK.

Chromosome Res. 1997 Apr;5(2):150. No abstract available.

PMID:
9146922
23.

Identification of PRG1, a novel progestin-responsive gene with sequence homology to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.

Hamilton JA, Callaghan MJ, Sutherland RL, Watts CK.

Mol Endocrinol. 1997 Apr;11(4):490-502.

PMID:
9092801
24.

D-penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding.

Handel ML, Watts CK, Sivertsen S, Day RO, Sutherland RL.

Mol Pharmacol. 1996 Sep;50(3):501-5.

PMID:
8794887
25.

High activity, soluble, bacterially expressed human vitamin D receptor and its ligand binding domain.

Mottershead DG, Polly P, Lyons RJ, Sutherland RL, Watts CK.

J Cell Biochem. 1996 Jun 1;61(3):325-37.

PMID:
8761938
26.

Cyclins and breast cancer.

Musgrove EA, Hui R, Sweeney KJ, Watts CK, Sutherland RL.

J Mammary Gland Biol Neoplasia. 1996 Apr;1(2):153-62. Review.

PMID:
10887489
27.

Cyclins and breast cancer.

Sweeney KJ, Musgrove EA, Watts CK, Sutherland RL.

Cancer Treat Res. 1996;83:141-70. Review. No abstract available.

PMID:
8826646
28.
29.

Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos.

Handel ML, Watts CK, deFazio A, Day RO, Sutherland RL.

Proc Natl Acad Sci U S A. 1995 May 9;92(10):4497-501.

30.

Steroidal regulation of cell cycle progression.

Sutherland RL, Hamilton JA, Sweeney KJ, Watts CK, Musgrove EA.

Ciba Found Symp. 1995;191:218-28; discussion 228-34. Review.

PMID:
8582199
31.

Expression and regulation of cyclin genes in breast cancer.

Sutherland RL, Hamilton JA, Sweeney KJ, Watts CK, Musgrove EA.

Acta Oncol. 1995;34(5):651-6. Review.

PMID:
7546834
33.
34.

Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells.

Watts CK, Sweeney KJ, Warlters A, Musgrove EA, Sutherland RL.

Breast Cancer Res Treat. 1994;31(1):95-105.

PMID:
7981461
35.

Cyclin gene expression and growth control in normal and neoplastic human breast epithelium.

Sutherland RL, Watts CK, Musgrove EA.

J Steroid Biochem Mol Biol. 1993 Dec;47(1-6):99-106. Review.

PMID:
8274447
36.

Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.

Hu XF, Veroni M, De Luise M, Wakeling A, Sutherland R, Watts CK, Zalcberg JR.

Int J Cancer. 1993 Nov 11;55(5):873-6.

PMID:
8244585
37.

Expression and amplification of cyclin genes in human breast cancer.

Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL.

Oncogene. 1993 Aug;8(8):2127-33.

PMID:
8336939
38.
39.

Comparative effects of gold on the interactions of transcription factors with DNA.

Handel ML, Sivertsen S, Watts CK, Day RO, Sutherland RL.

Agents Actions Suppl. 1993;44:219-23. Review.

PMID:
8372730
40.

Oestrogen receptor gene structure and function in breast cancer.

Watts CK, Handel ML, King RJ, Sutherland RL.

J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):529-36.

PMID:
1562523
41.

Inhibition of DNA binding and transcriptional activity of a nuclear receptor transcription factor by aurothiomalate and other metal ions.

Handel ML, deFazio A, Watts CK, Day RO, Sutherland RL.

Mol Pharmacol. 1991 Nov;40(5):613-8.

PMID:
1944234
42.

Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines.

Ewing TM, Murphy LJ, Ng ML, Pang GY, Lee CS, Watts CK, Sutherland RL.

Int J Cancer. 1989 Oct 15;44(4):744-52.

PMID:
2793247
43.

Stable transfection of the oestrogen receptor gene into a human osteosarcoma cell line.

Watts CK, Parker MG, King RJ.

J Steroid Biochem. 1989;34(1-6):483-90.

PMID:
2626043
44.

Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.

Watts CK, Sutherland RL.

Mol Pharmacol. 1987 May;31(5):541-51.

PMID:
3553893
45.

Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells.

Sutherland RL, Watts CK, Hall RE, Ruenitz PC.

J Steroid Biochem. 1987;27(4-6):891-7.

PMID:
3695509
48.
49.

Survey of Bicycling Accidents in Boulder, Colorado.

Watts CK, Jones D, Crouch D, Carter J, Mew L, Moseley B.

Phys Sportsmed. 1986 Mar;14(3):99-104. doi: 10.1080/00913847.1986.11709013.

PMID:
27467344
50.

High affinity specific antiestrogen binding sites are concentrated in rough microsomal membranes of rat liver.

Watts CK, Sutherland RL.

Biochem Biophys Res Commun. 1984 Apr 16;120(1):109-15.

PMID:
6712683

Supplemental Content

Loading ...
Support Center